Authorization

What Awaits Obseva (OBSV) On Monday?

(RTTNews) - Obseva SA (OBSV), a specialty biopharmaceutical company operating in the field of women's health and reproductive medicine, awaits a key catalyst on Monday.

The Company is slated to release six-month primary endpoint data from its phase III clinical trial of Linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids, dubbed PRIMROSE 2, on Monday, December 9, 2019. A conference call will be hosted that day at 8 a.m. Eastern Time, 2 p.m. Central European Time to discuss the results.

The PRIMROSE 2 trial is one of the two phase III studies evaluating Linzagolix in women with heavy menstrual bleeding (HMB) associated with uterine fibroids, and the other being PRIMROSE 1.

The PRIMROSE 1 and PRIMROSE 2 trials are testing the efficacy and safety of two doses of Linzagolix, including 100mg without low dose hormonal add-back therapy (ABT) and 200mg with ABT.

ObsEva in-licensed Linzagolix from Kissei Pharmaceutical Co. in 2015.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2020    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
2728293031